Yes, so uh for early intervention, so there is no study proven as that if you intervene early that would help, but having said that, uh, all these cancers, like in the metastatic stage, CA stomach or CA lung or CA of the hepatopancreatic structures, all these things generally they have a median survival of around 12 months, like if we have the data from all over the world...
Yes, so uh for early intervention, so there is no study proven as that if you intervene early that would help, but having said that, uh, all these cancers, like in the metastatic stage, CA stomach or CA lung or CA of the hepatopancreatic structures, all these things generally they have a median survival of around 12 months, like if we have the data from all over the world. So, before the advent of immunotherapy, it used to be ranged between 6 to 12 months only. So, you tend to intervene early in terms of the symptomatic management of anorexia and all those things. But again, the final outcome, a lot of it depends on how your patient is doing on the treatment for the specific diagnosis. Because if your patient has responded to the primary systemic therapy, they seem to be doing much better than those who have progressed on your primary systemic therapy. So, however, while you try in those patients using all these medicines, either megestrol acetate or olanzapine, or these days we have a few more groups of drugs as well, they don’t really seem to be doing much good to the patient, neither in terms of survival, nor in terms of symptomatic management.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
